As of November 6, 2026, Emmaus Life Sciences, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 17, 2026 (Form 8-K, April 17, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Emmaus Life Sciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Emmaus Life Sciences, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-17. Every row below is cited to the filing it comes from, and this page adds each new change as Emmaus Life Sciences, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-17 | Reported | not named in the filing | 8-K, 2026-04-17 |
Selling to them or working with them? See who runs Emmaus Life Sciences, Inc. now and the warning signs.
Free to see. No signup.
Watch Emmaus Life Sciences, Inc.
Get an email when Emmaus Life Sciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Emmaus Life Sciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Emmaus Life Sciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Emmaus Life Sciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
New leaders reset buying decisions — get the Full Report on Emmaus Life Sciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Emmaus Life Sciences, Inc., with the record behind each one.
Find candidates like senior executive at Emmaus Life Sciences, Inc.Every change, in the filing's words
Reported
Mr. Du is expected to also be appointed to replace Mr. Kuwahara as the sole member of the Audit Committee of the Board.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers Appointment of Director By written consent on April 16, 2026, the directors of Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" or the "company") appointed Henry H. Du to fill the vacancy on the Board of Directors created by the recent resignation of Jon Kuwahara.
- Mr. Du, age 48, has served as the Vice President - Finance Accounting and interim Chief Financial Officer of Alpha Cognition, Inc. (NASDAQ: ACOG), Grapevine, Texas, a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, since October 2024.
- Prior to joining Alpha Cognition, Inc., Mr. Du served in senior finance and accounting positions with a number of life sciences and other companies.
- Mr. Du is a Certified Public Accountant and holds a Bachelor of Arts degree from Claremont McKenna College, Claremont, California.
Tools for this story
Each opens in a new tab, filled in for Emmaus Life Sciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.